Charles Schwab Investment Management Inc. Purchases 80,923 Shares of Humana Inc. (NYSE:HUM)

Key Points

• Charles Schwab Investment Management Inc. increased its stake in Humana Inc. by 8.4%, owning over 1 million shares valued at approximately $276.7 million.
• The company reported earnings of $6.27 per share, slightly missing estimates, although its revenue increased by 9.6% year-over-year.
• Analysts have a consensus "Hold" rating on Humana, with a price target averaging $281.62, following various adjustments in their ratings.

Charles Schwab Investment Management Inc. lifted its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 8.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,045,849 shares of the insurance provider's stock after acquiring an additional 80,923 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.87% of Humana worth $276,732,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in HUM. Dodge & Cox boosted its holdings in Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider's stock worth $2,587,345,000 after purchasing an additional 5,264,045 shares during the last quarter. Vanguard Group Inc. lifted its stake in Humana by 8.9% in the first quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock valued at $3,697,222,000 after acquiring an additional 1,143,662 shares during the last quarter. GAMMA Investing LLC lifted its stake in Humana by 40,881.1% in the first quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider's stock valued at $2,066,790,000 after acquiring an additional 779,193 shares during the last quarter. Southpoint Capital Advisors LP acquired a new stake in Humana in the fourth quarter valued at $190,282,000. Finally, 8 Knots Management LLC acquired a new stake in Humana in the fourth quarter valued at $145,258,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Stock Performance

NYSE:HUM traded up $8.50 during mid-day trading on Tuesday, reaching $275.17. 1,547,001 shares of the company's stock were exchanged, compared to its average volume of 1,738,583. Humana Inc. has a one year low of $206.87 and a one year high of $382.72. The firm has a market capitalization of $33.09 billion, a PE ratio of 21.12, a price-to-earnings-growth ratio of 1.57 and a beta of 0.44. The business's fifty day simple moving average is $238.61 and its two-hundred day simple moving average is $253.70. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%. The business had revenue of $32.39 billion for the quarter, compared to the consensus estimate of $31.85 billion. During the same period in the prior year, the business posted $6.96 earnings per share. Humana's revenue was up 9.6% compared to the same quarter last year. Analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have commented on HUM. Morgan Stanley cut their price target on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating for the company in a research note on Thursday, July 31st. Robert W. Baird cut their price target on shares of Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a research note on Friday, July 25th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $290.00 price target on shares of Humana in a research note on Thursday, May 1st. Oppenheimer increased their price target on shares of Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a research note on Thursday, May 1st. Finally, Raymond James Financial upgraded shares of Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price target for the company in a research note on Thursday, May 1st. Seventeen investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, Humana presently has a consensus rating of "Hold" and an average target price of $281.62.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.